Cell Therapy Platform Enhanced: Charles River and Akron Bio Integrate CGMP Materials

Cell Therapy Platform Enhanced: Charles River and Akron Bio Integrate CGMP Materials Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio, a leading supplier of critical materials and services for advanced therapies, have announced a new collaboration to integrate…

Read MoreCell Therapy Platform Enhanced: Charles River and Akron Bio Integrate CGMP Materials

NextGen Healthcare Launches NextGen® Gastro Suite to Enhance GI Care

NextGen Healthcare Launches NextGen® Gastro Suite to Enhance GI Care NextGen Healthcare, a leader in healthcare technology innovation, has introduced the NextGen® Gastro Suite, a new solution designed to integrate gastroenterology-specific workflows into the NextGen® Enterprise EHR (electronic health record).…

Read MoreNextGen Healthcare Launches NextGen® Gastro Suite to Enhance GI Care

Inflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy

Inflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy Inflammasome Therapeutics, a clinical-stage biotech company at the forefront of developing dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative diseases, has announced promising topline results from a clinical trial…

Read MoreInflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy

Sinaptica Launches Co-Development of SinaptiStim® for Alzheimer’s, Pivotal Trial Set for 2025

Sinaptica Launches Co-Development of SinaptiStim® for Alzheimer’s, Pivotal Trial Set for 2025 Sinaptica Therapeutics, Inc., a clinical-stage company at the forefront of developing personalized neuromodulation treatments for Alzheimer’s and other neurodegenerative diseases, has announced the initiation of co-development for the…

Read MoreSinaptica Launches Co-Development of SinaptiStim® for Alzheimer’s, Pivotal Trial Set for 2025

SurGenTec Gains FDA Clearance for OsteoFlo® HydroFiber™ for Stand-Alone Use

SurGenTec Gains FDA Clearance for OsteoFlo® HydroFiber™ for Stand-Alone Use SurGenTec is excited to announce that its innovative product, OsteoFlo HydroFiber, has received FDA 510(k) clearance, marking a major milestone in the evolution of bone graft technology. This clearance establishes…

Read MoreSurGenTec Gains FDA Clearance for OsteoFlo® HydroFiber™ for Stand-Alone Use

Cancer Research Accelerated: Guardant Health and ConcertAI Launch Data-As-A-Service

Cancer Research Accelerated: Guardant Health and ConcertAI Launch Data-As-A-Service Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, and ConcertAI, a top provider of oncology real-world evidence (RWD) data and AI-driven SaaS technology, have announced a new collaboration. This…

Read MoreCancer Research Accelerated: Guardant Health and ConcertAI Launch Data-As-A-Service

Neurodegenerative Disease Imaging and Biomarkers: Enigma and UW-Madison Partner

Neurodegenerative Disease Imaging and Biomarkers: Enigma and UW-Madison Partner Enigma Biomedical USA, Inc. (Enigma) and the University of Wisconsin–Madison (UW–Madison) have announced a new partnership aimed at advancing the development of next-generation Positron Emission Tomography (PET) imaging and fluid biomarkers…

Read MoreNeurodegenerative Disease Imaging and Biomarkers: Enigma and UW-Madison Partner

Massive Bio Recognized by White House Cancer Moonshot, Launches $15M Initiative at JPM 2025

Massive Bio Recognized by White House Cancer Moonshot, Launches $15M Initiative at JPM 2025 Massive Bio is proud to announce its inclusion in the White House Office of Science & Technology Policy’s upcoming Cancer Moonshot Fact Sheet, highlighting its innovative…

Read MoreMassive Bio Recognized by White House Cancer Moonshot, Launches $15M Initiative at JPM 2025

Reports Positive Results from RESTORE Trial of ReActiv8® by Mainstay Medical

Reports Positive Results from RESTORE Trial of ReActiv8® by Mainstay Medical Mainstay Medical Holdings plc reports today the publication of positive one-year results from the RESTORE randomized clinical trial of ReActiv8®, a treatment for intractable chronic low back pain. The…

Read MoreReports Positive Results from RESTORE Trial of ReActiv8® by Mainstay Medical